2022 Update of the ADA Standards of Medical Care Highlight the Strength of Evidence Supporting rtCGM

Real-time continuous glucose monitoring (RT-CGM) remains a key technologic advancement recommended for integration into the management of diabetes according to the American Diabetes Association (ADA) Standards of Care (SOC) 2022. ADA assigned Grade A evidence to the recommendation that RT-CGM be offered for diabetes management in adults with diabetes on multiple daily injections (MDI) of insulin or continuous subcutaneous insulin infusion (CSII). Similarly, the ADA assigned Grade A evidence to the recommendation that RT- CGM be used for diabetes management in adults with diabetes on basal insulin. ADA’s criteria for a Grade A designation is defined as clear evidence from well-conducted, generalizable randomized controlled trials that are adequately powered.

American Diabetes Association Professional Practice Committee, et al. 7. Diabetes Technology: Standards of Medical Care in Diabetes-2022. Diabetes Care. 2022;45(Suppl 1):S97-S112.